Aeglea BioTherapeutics (NASDAQ:AGLE) Given New $17.00 Price Target at HC Wainwright

Aeglea BioTherapeutics (NASDAQ:AGLEGet Rating) had its target price lowered by HC Wainwright from $20.00 to $17.00 in a report published on Thursday, The Fly reports.

Several other analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Aeglea BioTherapeutics from a sell rating to a hold rating in a research note on Wednesday, March 30th. StockNews.com assumed coverage on shares of Aeglea BioTherapeutics in a research note on Thursday, March 31st. They issued a hold rating for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Aeglea BioTherapeutics has an average rating of Buy and a consensus target price of $13.05.

Shares of NASDAQ:AGLE opened at $1.58 on Thursday. The company has a market cap of $77.99 million, a price-to-earnings ratio of -1.58 and a beta of 1.60. Aeglea BioTherapeutics has a 12 month low of $1.40 and a 12 month high of $8.50. The company has a 50-day moving average price of $2.19 and a 200 day moving average price of $4.07.

Aeglea BioTherapeutics (NASDAQ:AGLEGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). As a group, equities research analysts predict that Aeglea BioTherapeutics will post -1.43 earnings per share for the current fiscal year.

In related news, CEO Anthony G. Quinn acquired 80,079 shares of the firm’s stock in a transaction dated Wednesday, March 16th. The shares were purchased at an average cost of $2.34 per share, for a total transaction of $187,384.86. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Jonathan Alspaugh acquired 75,000 shares of the company’s stock in a transaction on Friday, March 11th. The stock was purchased at an average cost of $2.08 per share, for a total transaction of $156,000.00. The disclosure for this purchase can be found here. Insiders have bought 257,328 shares of company stock valued at $545,246 in the last three months. Corporate insiders own 3.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of Aeglea BioTherapeutics in the fourth quarter valued at $48,000. Barclays PLC increased its holdings in shares of Aeglea BioTherapeutics by 191.5% in the 3rd quarter. Barclays PLC now owns 16,524 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 10,856 shares during the period. Suvretta Capital Management LLC increased its stake in Aeglea BioTherapeutics by 3.0% during the 3rd quarter. Suvretta Capital Management LLC now owns 2,157,727 shares of the biotechnology company’s stock valued at $17,154,000 after buying an additional 63,627 shares during the period. Goldman Sachs Group Inc. increased its stake in Aeglea BioTherapeutics by 0.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,136,050 shares of the biotechnology company’s stock valued at $9,031,000 after buying an additional 4,991 shares during the period. Finally, Geode Capital Management LLC increased its stake in Aeglea BioTherapeutics by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 689,997 shares of the biotechnology company’s stock valued at $5,485,000 after buying an additional 12,271 shares during the period. 84.13% of the stock is owned by hedge funds and other institutional investors.

Aeglea BioTherapeutics Company Profile (Get Rating)

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.

See Also

The Fly logo

Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.